Switching it up for a liver-friendly treatment! This new CTN study seeks to identify a treatment that is easier on the liver for people living with both HIV and hepatitis C, reducing liver fibrosis, cirrhosis, and liver disease. "Research has led to many advancements in treating HIV but we haven't slowed the progression of hepatitis C very well," says Dr. Klein, principal investigator on CTN 260 — Raltegravir switch study. "We need some other ways of slowing and managing liver fibrosis." The study will evaluate the safety and feasibility of switching from a ritonavir boosted PI-based therapy to raltegravir in co-infected persons with significant liver fibrosis. Using a special non-invasive and low-risk ultrasound called the Fibroscan, the researchers will measure changes in liver stiffness. The study seeks 40 patients to participate in the study, and is now enrolling in Montreal, Ottawa, Toronto, and Vancouver.
Switching it up for a liver-friendly treatment! This new CTN study seeks to identify a treatment that is easier on the liver for people living with both HIV and hepatitis C, reducing liver fibrosis, cirrhosis, and liver disease. "Research has led to many advancements in treating HIV but we haven't slowed the progression of hepatitis C very well," says Dr. Klein, principal investigator on CTN 260 — Raltegravir switch study. "We need some other ways of slowing and managing liver fibrosis." The study will evaluate the safety and feasibility of switching from a ritonavir boosted PI-based therapy to raltegravir in co-infected persons with significant liver fibrosis. Using a special non-invasive and low-risk ultrasound called the Fibroscan, the researchers will measure changes in liver stiffness. The study seeks 40 patients to participate in the study, and is now enrolling in Montreal, Ottawa, Toronto, and Vancouver.
